![Federico Sottotetti's research works | Istituti Clinici Scientifici Maugeri IRCCS, Pavia (Fondazione Maugeri) and other places Federico Sottotetti's research works | Istituti Clinici Scientifici Maugeri IRCCS, Pavia (Fondazione Maugeri) and other places](https://www.researchgate.net/publication/349954295/figure/fig1/AS:1020689633009666@1620362780542/The-figure-shows-the-CONSORT-flow-chart_Q320.jpg)
Federico Sottotetti's research works | Istituti Clinici Scientifici Maugeri IRCCS, Pavia (Fondazione Maugeri) and other places
![Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study - Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study - Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio](https://journals.sagepub.com/cms/10.1177/1758835919895755/asset/images/large/10.1177_1758835919895755-fig1.jpeg)
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study - Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge
![IJMS | Free Full-Text | Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer IJMS | Free Full-Text | Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer](https://www.mdpi.com/ijms/ijms-23-06320/article_deploy/html/images/ijms-23-06320-g001.png)